APOE and Atherosclerotic lesion: Finally, our previous study demonstrated that BSA-SeNPs, at the dose of 50 μg Se/kg body weight/day, alleviated atherosclerotic lesions after oral administration for 8 or 12 weeks [26,27], but aggravated atherosclerotic lesions and exhibited toxicity to the liver and kidneys after long-term administration (24 weeks) in ApoE-/- mice [55].